A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier.

Yi Song Thomas Boerner Esther Drill Paul Shin Sandeep Kumar Carlie S Sigel Andrea Cercek Nancy E Kemeny Ghassan K Abou-Alfa Christine A Iacobuzio-Donahue Darren Cowzer Nikolaus Schultz Henry S Walch Vinod P Balachandran Bas Groot Koerkamp Thomas Peter Kingham Kevin C Soares Alice C Wei Michael I D'Angelica Jeffrey A Drebin Rohit Chandwani James J Harding William R Jarnagin

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

IHC genetics form a spectrum with worse OS for tumors genetically aligned with EHC/GBC. The classifier proved superior to histologic subtypes for predicting OS independent of FGFR2 and IDH1 alterations. These results may explain the differential treatment responses seen in IHC and may direct therapy by helping stratify patients in future clinical trials.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
randomized controlled trial
stem cells
patient reported outcomes
gene expression
replacement therapy
patient reported